Report Details:
15 Companies Covered
65 Pages
Market Research Future (MRFR) has published a comprehensive research report on the MEA Diabetes Market, covering the forecast period from 2025 to 2035. According to the analysis, the MEA Diabetes Market was valued at USD 0.686 billion in 2024 and is projected to grow significantly, reaching USD 1.29 billion by 2035, registering a compound annual growth rate (CAGR) of 5.93% during the forecast period.
MRFR identifies Novo Nordisk (DK), Sanofi (FR), Boehringer Ingelheim (DE), AstraZeneca (GB), Merck & Co. (US), Johnson & Johnson (US), Abbott Laboratories (US), Roche (CH), and Eli Lilly and Company (US) as the key players operating in the MEA Diabetes Market.
Market Highlights
The MEA Diabetes Market is accounted for to register a CAGR of 5.93% during the forecast period and is estimated to reach USD 1.29 billion by 2035.
The increasing prevalence of diabetes across the Middle East and Africa is a major factor driving market growth. Rapid urbanization, sedentary lifestyles, unhealthy dietary habits, and rising obesity rates have significantly increased the burden of diabetes, particularly across GCC countries, prompting governments and healthcare providers to strengthen diabetes prevention and management initiatives.
Technological advancements in diabetes care are significantly influencing market expansion. The growing adoption of continuous glucose monitoring (CGM) systems, advanced insulin delivery devices, telemedicine platforms, and mobile health applications is improving disease management, enhancing patient engagement, and enabling more personalized diabetes care across the region.
Rising healthcare expenditure and supportive government initiatives are further accelerating market demand. Increased investments in healthcare infrastructure, favorable regulatory frameworks, public awareness campaigns, and diabetes education programs are improving access to diagnosis, treatment, and long-term disease management.
Additionally, increasing demand for innovative diabetes management solutions, expansion of digital health technologies, aging populations, and growing adoption of AI-enabled healthcare solutions are creating significant growth opportunities for diabetes care providers across the MEA region.
Segment Analysis
The MEA Diabetes Market is segmented based on Type of Diabetes, Treatment Method, Patient Demographics, and Complications.
By Type of Diabetes, the market includes Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes, LADA Diabetes, and MODY Diabetes. Type 2 Diabetes holds the largest market share due to its high prevalence associated with obesity, sedentary lifestyles, and aging populations. Type 1 Diabetes is the fastest-growing segment owing to increasing awareness, improved diagnostic capabilities, and expanding access to specialized treatment options.
By Treatment Method, the market includes Insulin Therapy, Oral Medications, Dietary Management, Physical Activity, and Continuous Glucose Monitoring. Insulin Therapy dominates the market due to its established role in diabetes management and widespread clinical adoption. Continuous Glucose Monitoring is the fastest-growing segment as patients and healthcare providers increasingly adopt real-time glucose monitoring technologies to improve treatment outcomes and disease management.
By Patient Demographics, the market includes Children, Adults, Elderly, Pregnant Women, and Obese Individuals. Adults account for the largest market share due to the high prevalence of lifestyle-related diabetes. Children represent the fastest-growing segment, driven by rising incidence of Type 1 diabetes, increasing childhood obesity, and growing awareness of early diagnosis and treatment.
By Complications, the market includes Cardiovascular Disease, Neuropathy, Nephropathy, Retinopathy, and Foot Ulcers. Cardiovascular Disease remains the largest complication segment due to its strong association with diabetes-related morbidity and mortality. Neuropathy is the fastest-growing complication segment owing to increased awareness, improved diagnosis, and greater emphasis on preventing long-term diabetes complications.
Region Analysis
Regionally, the MEA Diabetes Market is witnessing steady growth across GCC Countries, South Africa, and the Rest of the Middle East & Africa, supported by rising diabetes prevalence, healthcare modernization, and increasing investments in chronic disease management.
The GCC countries hold the largest market share, driven by high diabetes prevalence, increasing healthcare expenditure, advanced healthcare infrastructure, and supportive government initiatives promoting diabetes awareness and disease management. Countries such as Saudi Arabia and the UAE continue to invest heavily in diabetes treatment programs and innovative healthcare technologies.
South Africa represents the fastest-growing regional market, supported by rapid urbanization, increasing adoption of advanced diabetes management technologies, growing awareness of diabetes prevention, and expanding access to healthcare services. The adoption of continuous glucose monitoring devices and digital health platforms is accelerating market growth across the country.
The Rest of MEA is also witnessing considerable growth due to increasing diabetes prevalence, expanding healthcare reforms, improving access to affordable diabetes care, and rising investments in healthcare infrastructure aimed at addressing chronic diseases across underserved populations.
Key Findings of the Study
- The MEA Diabetes Market is projected to grow at a CAGR of 5.93% during the forecast period.
- The market is expected to reach USD 1.29 billion by 2035, driven by increasing diabetes prevalence, rising healthcare expenditure, and growing adoption of advanced diabetes management technologies.
- Type 2 Diabetes holds the largest market share due to its widespread prevalence, while Type 1 Diabetes is the fastest-growing segment owing to improved diagnosis and increasing disease awareness.
- Insulin Therapy remains the leading treatment method, while Continuous Glucose Monitoring (CGM) is witnessing the fastest growth driven by technological advancements and increasing patient preference for real-time glucose monitoring.
- Adults account for the largest patient demographic, while Children represent the fastest-growing segment due to rising childhood diabetes incidence and increasing healthcare awareness.
- Cardiovascular Disease remains the leading diabetes-related complication, while Neuropathy is expected to witness the fastest growth due to improved diagnosis and greater focus on complication management.
- GCC countries account for the largest regional market share, while South Africa is expected to register the fastest growth owing to increasing adoption of advanced diabetes technologies, urbanization, and healthcare modernization.
- Expansion of telehealth services, AI-driven predictive analytics, personalized insulin delivery systems, continuous glucose monitoring technologies, and supportive government healthcare initiatives continue to create significant opportunities across the MEA Diabetes Market.
Novo Nordisk, Sanofi, Boehringer Ingelheim, AstraZeneca, Merck & Co., Johnson & Johnson, Abbott Laboratories, Roche, and Eli Lilly and Company are among the leading companies driving innovation and competition in the MEA Diabetes Market.
